Green Meadow Ventures — 2017 Investments
1 investments dated 2017 · listed companies and verified rows first · show all
Angiexangiex.comin𝕏Jul 2017
Angiex develops Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) therapies for solid cancers, using a platform that delivers chemotherapeutic payloads to the nucleus of tumor cells and tumor blood vessel endothelial cells.
BiotechHealthtechMedical DevicesCambridge, US
Paul Jaminet(Executive Officer, Director)in
BoardErrik Anderson(Director)Jason Camm(Director)inIain Dukes(Director)inJonathan Adams(Director)inFabian Hansen(Director)in
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.